Format

Send to

Choose Destination
Medicine (Baltimore). 2019 Oct;98(42):e17486. doi: 10.1097/MD.0000000000017486.

A meta-analysis of cisplatin-based concurrent chemoradiotherapy with or without cetuximab for locoregionally advanced nasopharyngeal carcinoma.

Author information

1
Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology.
2
Department of Dermatology, The First Hospital of Wuhan, Wuhan, China.

Abstract

BACKGROUND:

It is unclear whether cetuximab (CTX) plus cisplatin-based concurrent chemoradiotherapy (CCRT) delivers equivalent or improved results over standard CCRT in locoregionally advanced nasopharyngeal carcinoma (NPC).

METHODS:

The strategy involved searching the PubMed, Embase, Cochrane Library, and Web of Science. Pooled hazard ratios (HRs) for overall survival (OS), distant metastasis-free survival (DMFS), locoregional relapse-free survival (LRFS), and disease-free survival (DFS), and pooled risk ratios for adverse events were meta-analyzed.

RESULTS:

In all, 1744 patients in 5 clinical trials were included in the analysis. Compared with CCRT group, CTX plus CCRT significantly improved DFS (HR = 0.59, 95% confidence interval [CI]: 0.41-0.86, P = .006) and distant metastasis failure-free survival (HR = 0.54, 95% CI: 0.38-0.76, P = .0004), rather than OS (HR = 0.70, 95% CI: 0.44-1.09, P = .12) and local-regional failure-free survival (HR = 0.82, 95% CI: 0.54-1.22, P = .33).

CONCLUSIONS:

CTX plus CCRT might achieve higher DFS and DMFS with no significant difference in OS and LRFS. CTX plus CCRT group was associated with more grade 3-4 skin rash, mucositis and dermatitis. Large randomized trials were urgent to fully explore the usefulness of this treatment in the locally advanced NPC patients.

PMID:
31626102
DOI:
10.1097/MD.0000000000017486
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Wolters Kluwer
Loading ...
Support Center